glaxosmithkline plc glaxosmithkline plc said it has the potential to launch five new cancer drugs in the next three years to treat a broad range of tumors the products are cervical cancer vaccine cervarix which is expected to be launched in europe this year kidney cancer drug pazopanib blood platelet booster promacta nausea drug rezonic and humax cd a lymphoma treatment being developed with danish biotechnology company genmab as the drugs are expected to follow the march launch in the u s of breast cancer pill tykerb which glaxosmithkline said it had a very good start with about patients treated since it became available the british pharmaceutical company said that by the end of this year or early next year it expects to file for marketing approval of promacta to treat idiopathic thrombocytopenic purpura or itp in which the blood doesnt clot as it should glaxo expects to file for market approval of rezonic in the first half of next year humax cd is expected to start late stage clinical trials for the treatment of rheumatoid arthritis by the end of the drug which was discovered by glaxosmithklines partner genmab is also in late stage development for chronic lymphocytic leukemia as well as non hodgkins lymphoma 
